Toxoplasmosis is a contagious illness that is brought on by the parasite Toxoplasma gondii.
The strain of Toxoplasma gondii may have an effect on how severe the symptoms of toxoplasmosis
are. Immunocompromised people are more likely to develop neurological, ocular,
and systemic diseases as a result of toxoplasmosis. Rosuvastatin® is one of the promising
drugs in the treatment of toxoplasmosis. This study determined the rosuvastatin efficacy in
treating murine toxoplasmosis. This is being done in an effort to make up for the deficiencies
that are present in other standard medications. Mice were divided into 7 groups of 10 mice
each. GI: Neither infected nor treated (normal control). GII: Infected, non-treated mice (positive
control). GIII: Mice given Spiramycin® as prophylaxis before infection. GIV: Mice given
rosuvastatin as prophylaxis before infection. GV: Mice infected and treated by spiramycin after
6th week for 2 weeks. GVI: Mice infected and treated by rosuvastatin after 6th week for 2
weeks. GVII: Following the sixth week, infection was confirmed, and treatment consisted of a
combination of rosuvastatin and spiramycin for two weeks. Histological examination of brain
and liver, and counting brain cysts, were used to evaluate the efficacy of treatment.
The results showed that rosuvastatin treated group showed significant reduction in brain
cysts and improved histopathological picture in brain and liver tissue. Combination of rosuvastatin
and spiramycin gave the best results in reduction of brain cysts number and the least
pathological changes in brain and liver tissue. The effect of rosuvastatin was augmented after
combination with spiramycin.